| Wissenschaftl. Titel | A randomized, multicenter, open-label phase-III study to evaluate the efficacy and safety of transtuzumab emtasine versus trastuzumab as therapy for patients with HER2-positive adjuvant primary breast cancer who have residual tumor present pathology in the breast or axillary lymph nodes following preoperative therapy |
| Erkrankung |
Geschlechtsorgane:
Brustkrebs:
adjuvant
|
| Molekularer Marker |
HER2/neu pos. |
| weitere Prüfzentren | |
| Kurzprotokoll | Kurzprotokoll |
erstellt 05.11.2013 Johannes Kraus
geändert 26.02.2024 Admin04